RECURRENT LUNG NON-SMALL CELL CARCINOMA
Clinical trials for RECURRENT LUNG NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT LUNG NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT LUNG NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo aims to reignite immune attack on lung cancer
Disease control Not yet recruitingThis phase 2 trial tests whether combining SX-682 (a drug that blocks certain immune-suppressing proteins) with atezolizumab (an immunotherapy) can shrink tumors in people with advanced non-small cell lung cancer that has worsened after chemotherapy and immunotherapy. About 32 ad…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug combo aims to shrink Hard-to-Treat lung tumors
Disease control Not yet recruitingThis study tests two drugs, sacituzumab govitecan and ivonescimab, alone or together, in people with advanced non-small cell lung cancer that has specific gene changes. The goal is to see if the combination works better than either drug alone at shrinking tumors and delaying canc…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC